Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherArticle

Characterization of Enzymes Involved in Nintedanib Metabolism in Humans

Shimon Nakashima, Rei Sato, Tatsuki Fukami, Takashi Kudo, Shiori Hashiba, Gaku Morinaga, Masataka Nakano, Eva Ludwig-Schwellinger, Akiko Matsui, Naoki Ishiguro, Thomas Ebner and Miki Nakajima
Drug Metabolism and Disposition March 16, 2023, DMD-AR-2022-001113; DOI: https://doi.org/10.1124/dmd.122.001113
Shimon Nakashima
1Kanazawa University, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rei Sato
1Kanazawa University, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuki Fukami
1Kanazawa University, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Kudo
2Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Takashi Kudo
Shiori Hashiba
1Kanazawa University, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaku Morinaga
3Nippon Boehringer Ingelheim Co., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masataka Nakano
4Faculty of Pharmaceutical Sciences, Kanazawa University, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Ludwig-Schwellinger
5Boehringer Ingelheim Pharma GmbH & Co KG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akiko Matsui
6Nippon Boehringer Ingelheim Co., Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoki Ishiguro
7Pharmacokinetic and non-clinical safety, Kobe Pharma Research Institute, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Ebner
5Boehringer Ingelheim Pharma GmbH & Co KG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miki Nakajima
4Faculty of Pharmaceutical Sciences, Kanazawa University, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nmiki@p.kanazawa-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Nintedanib, which is used to treat idiopathic pulmonary fibrosis and non-small cell lung cancer, is metabolized to a pharmacologically inactive carboxylate derivative, BIBF1202, via hydrolysis and subsequently by glucuronidation to BIBF1202 acyl-glucuronide (BIBF1202-G). Since BIBF1202-G contains an ester bond, it can be hydrolytically cleaved to BIBF1202. In this study, we sought to characterize these metabolic reactions in the human liver and intestine. Nintedanib hydrolysis was detected in human liver microsomes (HLM) (CLint: 102.8 {plus minus} 18.9 µL/min/mg protein) but not in small intestinal preparations. CES1 was suggested to be responsible for nintedanib hydrolysis according to experiments using recombinant hydrolases and hydrolase inhibitors as well as proteomic correlation analysis using 25 individual HLM. BIBF1202 glucuronidation in HLM (3.6 {plus minus} 0.3 µL/min/mg protein) was higher than that in human intestinal microsomes (1.5 {plus minus} 0.06 µL/min/mg protein). UGT1A1 and gastrointestinal UGT1A7, UGT1A8, and UGT1A10 were able to mediate BIBF1202 glucuronidation. The impact of UGT1A1 on glucuronidation was supported by the finding that liver microsomes from subjects homozygous for the UGT1A1*28 allele showed significantly lower activity than those from subjects carrying the wild-type UGT1A1 allele. Interestingly, BIBF1202-G was converted to BIBF1202 in HLS9 at 70-fold higher rates than the rates of BIBF1202 glucuronidation. An inhibition study and proteomic correlation analysis suggested that b-glucuronidase is responsible for hepatic BIBF1202-G deglucuronidation. In conclusion, the major metabolic reactions of nintedanib in the human liver and intestine were quantitatively and thoroughly elucidated. This information could be helpful to understand the inter- and intraindividual variability in the efficacy of nintedanib.

Significance Statement To our knowledge, this is the first study to characterize the enzymes responsible for each step of nintedanib metabolism in the human body. We found that β-glucuronidase may contribute to BIBF1202-G deglucuronidation.

  • drug metabolism
  • enzyme
  • liver/hepatic
  • UDP glucuronosyltransferase (UGT)
  • Copyright © 2023 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 51 (3)
Drug Metabolism and Disposition
Vol. 51, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Enzymes Involved in Nintedanib Metabolism in Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Metabolic enzymes in nintedanib metabolism

Shimon Nakashima, Rei Sato, Tatsuki Fukami, Takashi Kudo, Shiori Hashiba, Gaku Morinaga, Masataka Nakano, Eva Ludwig-Schwellinger, Akiko Matsui, Naoki Ishiguro, Thomas Ebner and Miki Nakajima
Drug Metabolism and Disposition March 16, 2023, DMD-AR-2022-001113; DOI: https://doi.org/10.1124/dmd.122.001113

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Metabolic enzymes in nintedanib metabolism

Shimon Nakashima, Rei Sato, Tatsuki Fukami, Takashi Kudo, Shiori Hashiba, Gaku Morinaga, Masataka Nakano, Eva Ludwig-Schwellinger, Akiko Matsui, Naoki Ishiguro, Thomas Ebner and Miki Nakajima
Drug Metabolism and Disposition March 16, 2023, DMD-AR-2022-001113; DOI: https://doi.org/10.1124/dmd.122.001113
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics